[A22-41] Sacituzumab govitecan (breast cancer) - Addendum to Commission A21-154
Last updated 20.05.2022
Project no.:
A22-41
Commission:
Commission awarded on 13.04.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with unresectable or metastatic triple-negative breast cancer who have had two or more prior systemic therapies including at least one of them for advanced disease
After addendum now indication of major added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-154 | Sacituzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-05-20 A G-BA decision was published.